The rebound in the domestic pharma market’s growth is helping sentiments, even as its well-established branded portfolio aids prospects. Multinational pharmaceutical firms focused on the Indian market also remain insulated from the volatility seen by domestic pharma firms in export markets. Pricing pressure in the US or currency headwinds have been some of the factors that have impacted the performance of many domestic firms. During Q4, the firm had reported 14% y-o-y growth, outperforming the pharma market growth. The company has also shifted the manufacturing of two key products, Duphalac and Udiliv, to its Goa plant from third-party manufacturers and is in the process of shifting a few more products.

Source: Mint July 04, 2021 16:07 UTC